No

Antidepressant, Monoamine Oxidase Inhibitor

Symptomatic treatment of atypical, nonendogenous or neurotic depression

C

Uncontrolled hypertension; hypersensitivity to isocarboxazid; pheochromocytoma; congestive heart failure; severe renal or hepatic impairment

>10%:

Cardiovascular: Orthostatic hypotension

Central nervous system: Drowsiness

Endocrine & metabolic: Decreased sexual ability

Neuromuscular & skeletal: Weakness, trembling

Ocular: Blurred vision

1% to 10%:

Cardiovascular: Tachycardia, peripheral edema

Central nervous system: Nervousness, chills

Dermatologic: Xerostomia

Gastrointestinal: Diarrhea, anorexia, constipation

<1%:

Central nervous system: Parkinsonian syndrome

Hematologic: Leukopenia

Hepatic: Hepatitis

Decreased effect of antihypertensives

Increased toxicity with disulfiram (possible seizures), fluoxetine (and other serotonin active agents), TCAs (cardiovascular instability), meperidine (cardiovascular instability), phenothiazines (hyperpyretic crisis), levodopa, sympathomimetics (hyperpyretic crisis), barbiturates, rauwolfia alkaloids (eg, reserpine), dextroamphetamine (psychoses), foods containing tyramine

Thought to act by increasing endogenous concentrations of epinephrine, norepinephrine, dopamine, and serotonin through inhibition of the enzyme (monoamine oxidase) responsible for the breakdown of these neurotransmitters

Adults: Oral: 10 mg 3 times/day; reduce to 10-20 mg/day in divided doses when condition improves

Attempts should be made to avoid use of vasoconstrictor due to possibility of hypertensive episodes with monoamine oxidase inhibitors

Orthostatic hypotension in >10% of patients; meperidine should be avoided as an analgesic due to toxic reactions with MAO inhibitors

Avoid tyramine-containing foods and drinks

Tablet: 10 mg